Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies

Cancer Cell

Volumn 31, Issue 3, 2017, Pages 311-325

  Anderson, Kristin G ^a,b   Stromnes, Ingunn M ^a   Greenberg, Philip D ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

adoptive T cell therapy; genetic engineering; immunotherapy; T cell dysfunction; TME; tumor microenvironment

Indexed keywords

AMINO ACID; BETA CATENIN; FAS ANTIGEN; FAS LIGAND; FATTY ACID; GLUCOSE; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; LACTIC ACID; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN P53; REACTIVE OXYGEN METABOLITE; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ACIDIFICATION; AEROBIC GLYCOLYSIS; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW CELL; CANCER CONTROL; CD8+ T LYMPHOCYTE; CELL ENGINEERING; CELL SURVIVAL; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DENDRITIC CELL; EFFECTOR CELL; HUMAN; HYPOXIA; IMMUNE EVASION; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; MELANOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL DESTRUCTION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; CYTOTOXICITY; IMMUNOLOGY; METABOLISM; NEOPLASMS; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

AMINO ACIDS; CYTOTOXICITY, IMMUNOLOGIC; FATTY ACIDS; GENES, P53; GLUCOSE; HUMANS; LACTIC ACID; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 85015064348     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2017.02.008     Document Type: Review

References (202)

1. Baitsch, L., Baumgaertner, P., Devevre, E., Raghav, S.K., Legat, A., Barba, L., Wieckowski, S., Bouzourene, H., Deplancke, B., Romero, P., et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J. Clin. Invest. 121 (2011), 2350–2360.
2. Bayne, L.J., Beatty, G.L., Jhala, N., Clark, C.E., Rhim, A.D., Stanger, B.Z., Vonderheide, R.H., Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21 (2012), 822–835.
3. Beatty, G.L., Haas, A.R., Maus, M.V., Torigian, D.A., Soulen, M.C., Plesa, G., Chew, A., Zhao, Y., Levine, B.L., Albelda, S.M., et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol. Res. 2 (2014), 112–120.
4. Becker, J.C., Andersen, M.H., Schrama, D., Thor Straten, P., Immune-suppressive properties of the tumor microenvironment. Cancer Immunol. Immunother. 62 (2013), 1137–1148.
5. Benabdellah, K., Munoz, P., Cobo, M., Gutierrez-Guerrero, A., Sanchez-Hernandez, S., Garcia-Perez, A., Anderson, P., Carrillo-Galvez, A.B., Toscano, M.G., Martin, F., Lent-on-plus lentiviral vectors for conditional expression in human stem cells. Sci. Rep., 6, 2016, 37289.
6. Bengsch, B., Johnson, A.L., Kurachi, M., Odorizzi, P.M., Pauken, K.E., Attanasio, J., Stelekati, E., McLane, L.M., Paley, M.A., Delgoffe, G.M., Wherry, E.J., Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion. Immunity 45 (2016), 358–373.
7. Bernstorff, W.V., Glickman, J.N., Odze, R.D., Farraye, F.A., Joo, H.G., Goedegebuure, P.S., Eberlein, T.J., Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape. Cancer 94 (2002), 2552–2560.
8. Beura, L.K., Hamilton, S.E., Bi, K., Schenkel, J.M., Odumade, O.A., Casey, K.A., Thompson, E.A., Fraser, K.A., Rosato, P.C., Filali-Mouhim, A., et al. Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature 532 (2016), 512–516.
9. Bian, Y., Yu, Y., Wang, S., Li, L., Up-regulation of fatty acid synthase induced by EGFR/ERK activation promotes tumor growth in pancreatic cancer. Biochem. Biophys. Res. Commun. 463 (2015), 612–617.
10. Blackburn, S.D., Shin, H., Haining, W.N., Zou, T., Workman, C.J., Polley, A., Betts, M.R., Freeman, G.J., Vignali, D.A., Wherry, E.J., Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10 (2009), 29–37.
11. Bodnar, L., Stanczak, A., Cierniak, S., Smoter, M., Cichowicz, M., Kozlowski, W., Szczylik, C., Wieczorek, M., Lamparska-Przybysz, M., Wnt/beta-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer. J. Ovarian Res., 7, 2014, 16.
12. Boj, S.F., Hwang, C.I., Baker, L.A., Chio, I.I., Engle, D.D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M.S., et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160 (2015), 324–338.
13. Brahmer, J.R., Tykodi, S.S., Chow, L.Q., Hwu, W.J., Topalian, S.L., Hwu, P., Drake, C.G., Camacho, L.H., Kauh, J., Odunsi, K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366 (2012), 2455–2465.
14. Brand, A., Singer, K., Koehl, G.E., Kolitzus, M., Schoenhammer, G., Thiel, A., Matos, C., Bruss, C., Klobuch, S., Peter, K., et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 24 (2016), 657–671.
15. Brody, J.R., Costantino, C.L., Berger, A.C., Sato, T., Lisanti, M.P., Yeo, C.J., Emmons, R.V., Witkiewicz, A.K., Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle 8 (2009), 1930–1934.
16. Buck, M.D., O'Sullivan, D., Pearce, E.L., T cell metabolism drives immunity. J. Exp. Med. 212 (2015), 1345–1360.
17. Buckanovich, R.J., Facciabene, A., Kim, S., Benencia, F., Sasaroli, D., Balint, K., Katsaros, D., O'Brien-Jenkins, A., Gimotty, P.A., Coukos, G., Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med. 14 (2008), 28–36.
18. Carr, E.L., Kelman, A., Wu, G.S., Gopaul, R., Senkevitch, E., Aghvanyan, A., Turay, A.M., Frauwirth, K.A., Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J. Immunol. 185 (2010), 1037–1044.
19. Carvalho, K.C., Cunha, I.W., Rocha, R.M., Ayala, F.R., Cajaiba, M.M., Begnami, M.D., Vilela, R.S., Paiva, G.R., Andrade, R.G., Soares, F.A., GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics (Sao Paulo) 66 (2011), 965–972.
20. Cham, C.M., Driessens, G., O'Keefe, J.P., Gajewski, T.F., Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells. Eur. J. Immunol. 38 (2008), 2438–2450.
21. Chang, C.H., Pearce, E.L., Emerging concepts of T cell metabolism as a target of immunotherapy. Nat. Immunol. 17 (2016), 364–368.
22. Chang, C.H., Qiu, J., O'Sullivan, D., Buck, M.D., Noguchi, T., Curtis, J.D., Chen, Q., Gindin, M., Gubin, M.M., van der Windt, G.J., et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162 (2015), 1229–1241.
23. Chapman, N.M., Connolly, S.F., Reinl, E.L., Houtman, J.C., Focal adhesion kinase negatively regulates Lck function downstream of the T cell antigen receptor. J. Immunol. 191 (2013), 6208–6221.
24. Chapuis, A.G., Ragnarsson, G.B., Nguyen, H.N., Chaney, C.N., Pufnock, J.S., Schmitt, T.M., Duerkopp, N., Roberts, I.M., Pogosov, G.L., Ho, W.Y., et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci. Transl. Med., 5, 2013, 174ra127.
25. Cheng, L.E., Greenberg, P.D., Selective delivery of augmented IL-2 receptor signals to responding CD8+ T cells increases the size of the acute antiviral response and of the resulting memory T cell pool. J. Immunol. 169 (2002), 4990–4997.
26. Cho, H., Lee, Y.S., Kim, J., Chung, J.Y., Kim, J.H., Overexpression of glucose transporter-1 (GLUT-1) predicts poor prognosis in epithelial ovarian cancer. Cancer Invest. 31 (2013), 607–615.
27. Chou, C.K., Schietinger, A., Liggitt, H.D., Tan, X., Funk, S., Freeman, G.J., Ratliff, T.L., Greenberg, N.M., Greenberg, P.D., Cell-intrinsic abrogation of TGF-beta signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer. J. Immunol. 189 (2012), 3936–3946.
28. Cohen, R., Neuzillet, C., Tijeras-Raballand, A., Faivre, S., de Gramont, A., Raymond, E., Targeting cancer cell metabolism in pancreatic adenocarcinoma. Oncotarget 6 (2015), 16832–16847.
29. Colegio, O.R., Chu, N.Q., Szabo, A.L., Chu, T., Rhebergen, A.M., Jairam, V., Cyrus, N., Brokowski, C.E., Eisenbarth, S.C., Phillips, G.M., et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513 (2014), 559–563.
30. Collins, M.A., Bednar, F., Zhang, Y., Brisset, J.C., Galban, S., Galban, C.J., Rakshit, S., Flannagan, K.S., Adsay, N.V., Pasca di Magliano, M., Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J. Clin. Invest. 122 (2012), 639–653.
31. Corrales, L., Matson, V., Flood, B., Spranger, S., Gajewski, T.F., Innate immune signaling and regulation in cancer immunotherapy. Cell Res. 27 (2017), 96–108.
32. Curiel, T.J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J.R., Zhang, L., Burow, M., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 (2004), 942–949.
33. Daley, D., Zambirinis, C.P., Seifert, L., Akkad, N., Mohan, N., Werba, G., Barilla, R., Torres-Hernandez, A., Hundeyin, M., Mani, V.R., et al. Gammadelta T cells support pancreatic oncogenesis by restraining alphabeta T cell activation. Cell 166 (2016), 1485–1499.e15.
34. Davis-Yadley, A.H., Abbott, A.M., Pimiento, J.M., Chen, D.T., Malafa, M.P., Increased expression of the glucose transporter type 1 gene is associated with worse overall survival in resected pancreatic adenocarcinoma. Pancreas 45 (2016), 974–979.
35. DeBerardinis, R.J., Chandel, N.S., Fundamentals of cancer metabolism. Sci. Adv., 2, 2016, e1600200.
36. Eil, R., Vodnala, S.K., Clever, D., Klebanoff, C.A., Sukumar, M., Pan, J.H., Palmer, D.C., Gros, A., Yamamoto, T.N., Patel, S.J., et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature 537 (2016), 539–543.
37. Elston, R., Inman, G.J., Crosstalk between p53 and TGF-beta signalling. J. Signal. Transduct., 2012, 2012, 294097.
38. Emmrich, J., Weber, I., Nausch, M., Sparmann, G., Koch, K., Seyfarth, M., Lohr, M., Liebe, S., Immunohistochemical characterization of the pancreatic cellular infiltrate in normal pancreas, chronic pancreatitis and pancreatic carcinoma. Digestion 59 (1998), 192–198.
39. Ene-Obong, A., Clear, A.J., Watt, J., Wang, J., Fatah, R., Riches, J.C., Marshall, J.F., Chin-Aleong, J., Chelala, C., Gribben, J.G., et al. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology 145 (2013), 1121–1132.
40. Epstein, J.I., Carmichael, M., Partin, A.W., OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology 45 (1995), 81–86.
41. Fan, J., Kamphorst, J.J., Mathew, R., Chung, M.K., White, E., Shlomi, T., Rabinowitz, J.D., Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol. Syst. Biol., 9, 2013, 712.
42. Feig, C., Jones, J.O., Kraman, M., Wells, R.J., Deonarine, A., Chan, D.S., Connell, C.M., Roberts, E.W., Zhao, Q., Caballero, O.L., et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. USA 110 (2013), 20212–20217.
43. Feng, K., Guo, Y., Dai, H., Wang, Y., Li, X., Jia, H., Han, W., Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Sci. China Life Sci. 59 (2016), 468–479.
44. Filipp, F.V., Ratnikov, B., De Ingeniis, J., Smith, J.W., Osterman, A.L., Scott, D.A., Glutamine-fueled mitochondrial metabolism is decoupled from glycolysis in melanoma. Pigment Cell Melanoma Res 25 (2012), 732–739.
45. Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., Gottfried, E., Schwarz, S., Rothe, G., Hoves, S., et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109 (2007), 3812–3819.
46. Forbes, S.A., Bindal, N., Bamford, S., Cole, C., Kok, C.Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res. 39 (2011), D945–D950.
47. Foster, A.E., Dotti, G., Lu, A., Khalil, M., Brenner, M.K., Heslop, H.E., Rooney, C.M., Bollard, C.M., Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J. Immunother. 31 (2008), 500–505.
48. Frame, M.C., Patel, H., Serrels, B., Lietha, D., Eck, M.J., The FERM domain: organizing the structure and function of FAK. Nat. Rev. Mol. Cell Biol. 11 (2010), 802–814.
49. Galon, J., Angell, H.K., Bedognetti, D., Marincola, F.M., The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39 (2013), 11–26.
50. Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006), 1960–1964.
51. Gansler, T.S., Hardman, W. 3rd, Hunt, D.A., Schaffel, S., Hennigar, R.A., Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum. Pathol. 28 (1997), 686–692.
52. Geiger, R., Rieckmann, J.C., Wolf, T., Basso, C., Feng, Y., Fuhrer, T., Kogadeeva, M., Picotti, P., Meissner, F., Mann, M., et al. L-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 167 (2016), 829–842.e813.
53. Giordano, M., Henin, C., Maurizio, J., Imbratta, C., Bourdely, P., Buferne, M., Baitsch, L., Vanhille, L., Sieweke, M.H., Speiser, D.E., et al. Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. EMBO J. 34 (2015), 2042–2058.
54. Grohmann, U., Fallarino, F., Puccetti, P., Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 24 (2003), 242–248.
55. Guillaumond, F., Leca, J., Olivares, O., Lavaut, M.N., Vidal, N., Berthezene, P., Dusetti, N.J., Loncle, C., Calvo, E., Turrini, O., et al. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc. Natl. Acad. Sci. USA 110 (2013), 3919–3924.
56. Guirnalda, P., Wood, L., Goenka, R., Crespo, J., Paterson, Y., Interferon gamma-induced intratumoral expression of CXCL9 alters the local distribution of T cells following immunotherapy with Listeria monocytogenes. Oncoimmunology, 2, 2013, e25752.
57. Gunderson, A.J., Kaneda, M.M., Tsujikawa, T., Nguyen, A.V., Affara, N.I., Ruffell, B., Gorjestani, S., Liudahl, S.M., Truitt, M., Olson, P., et al. Bruton's tyrosine kinase (BTK)-dependent immune cell crosstalk drives pancreas cancer. Cancer Discov. 6 (2015), 270–285.
58. Haddad, R., Saldanha-Araujo, F., Mechanisms of T-cell immunosuppression by mesenchymal stromal cells: what do we know so far?. Biomed. Res. Int., 2014, 2014, 216806.
59. Hamid, O., Robert, C., Daud, A., Hodi, F.S., Hwu, W.J., Kefford, R., Wolchok, J.D., Hersey, P., Joseph, R.W., Weber, J.S., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369 (2013), 134–144.
60. Hanahan, D., Coussens, L.M., Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21 (2012), 309–322.
61. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
62. Harlin, H., Meng, Y., Peterson, A.C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., Gajewski, T.F., Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 69 (2009), 3077–3085.
63. He, C., Duan, X., Guo, N., Chan, C., Poon, C., Weichselbaum, R.R., Lin, W., Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. Nat. Commun., 7, 2016, 12499.
64. Hensley, C.T., Wasti, A.T., DeBerardinis, R.J., Glutamine and cancer: cell biology, physiology, and clinical opportunities. J. Clin. Invest. 123 (2013), 3678–3684.
65. Ho, P.C., Bihuniak, J.D., Macintyre, A.N., Staron, M., Liu, X., Amezquita, R., Tsui, Y.C., Cui, G., Micevic, G., Perales, J.C., et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162 (2015), 1217–1228.
66. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (2010), 711–723.
67. Hodis, E., Watson, I.R., Kryukov, G.V., Arold, S.T., Imielinski, M., Theurillat, J.P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. A landscape of driver mutations in melanoma. Cell 150 (2012), 251–263.
68. Holmgaard, R.B., Zamarin, D., Li, Y., Gasmi, B., Munn, D.H., Allison, J.P., Merghoub, T., Wolchok, J.D., Tumor-expressed IDO recruits and activates MDSCs in a treg-dependent manner. Cell Rep. 13 (2015), 412–424.
69. Hoseini, S.S., Hapke, M., Herbst, J., Wedekind, D., Baumann, R., Heinz, N., Schiedlmeier, B., Vignali, D.A., van den Brink, M.R., Schambach, A., et al. Inducible T-cell receptor expression in precursor T cells for leukemia control. Leukemia 29 (2015), 1530–1542.
70. Hugo, W., Zaretsky, J.M., Sun, L., Song, C., Moreno, B.H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165 (2016), 35–44.
71. Husain, Z., Huang, Y., Seth, P., Sukhatme, V.P., Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J. Immunol. 191 (2013), 1486–1495.
72. Inaba, T., Ino, K., Kajiyama, H., Yamamoto, E., Shibata, K., Nawa, A., Nagasaka, T., Akimoto, H., Takikawa, O., Kikkawa, F., Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol. Oncol. 115 (2009), 185–192.
73. Innocenzi, D., Alo, P.L., Balzani, A., Sebastiani, V., Silipo, V., La Torre, G., Ricciardi, G., Bosman, C., Calvieri, S., Fatty acid synthase expression in melanoma. J. Cutan. Pathol. 30 (2003), 23–28.
74. Jacobs, S.R., Herman, C.E., Maciver, N.J., Wofford, J.A., Wieman, H.L., Hammen, J.J., Rathmell, J.C., Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J. Immunol. 180 (2008), 4476–4486.
75. Jiang, H., Hegde, S., Knolhoff, B.L., Zhu, Y., Herndon, J.M., Meyer, M.A., Nywening, T.M., Hawkins, W.G., Shapiro, I.M., Weaver, D.T., et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat. Med. 22 (2016), 851–860.
76. Kaech, S.M., Cui, W., Transcriptional control of effector and memory CD8+ T cell differentiation. Nat. Rev. Immunol. 12 (2012), 749–761.
77. Kaira, K., Sunose, Y., Arakawa, K., Ogawa, T., Sunaga, N., Shimizu, K., Tominaga, H., Oriuchi, N., Itoh, H., Nagamori, S., et al. Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. Br. J. Cancer 107 (2012), 632–638.
78. Kaira, K., Nakamura, K., Hirakawa, T., Imai, H., Tominaga, H., Oriuchi, N., Nagamori, S., Kanai, Y., Tsukamoto, N., Oyama, T., et al. Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in patients with ovarian tumors. Am. J. Transl. Res. 7 (2015), 1161–1171.
79. Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A., June, C.H., T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med., 3, 2011, 95ra73.
80. Kershaw, M.H., Westwood, J.A., Parker, L.L., Wang, G., Eshhar, Z., Mavroukakis, S.A., White, D.E., Wunderlich, J.R., Canevari, S., Rogers-Freezer, L., et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12 (2006), 6106–6115.
81. Kim, H., Peng, G., Hicks, J.M., Weiss, H.L., Van Meir, E.G., Brenner, M.K., Yotnda, P., Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment. Mol. Ther. 16 (2008), 599–606.
82. Kleffel, S., Posch, C., Barthel, S.R., Mueller, H., Schlapbach, C., Guenova, E., Elco, C.P., Lee, N., Juneja, V.R., Zhan, Q., et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell 162 (2015), 1242–1256.
83. Konstantinidou, G., Ramadori, G., Torti, F., Kangasniemi, K., Ramirez, R.E., Cai, Y., Behrens, C., Dellinger, M.T., Brekken, R.A., Wistuba, I.I., et al. RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. Cancer Discov. 3 (2013), 444–457.
84. Koong, A.C., Mehta, V.K., Le, Q.T., Fisher, G.A., Terris, D.J., Brown, J.M., Bastidas, A.J., Vierra, M., Pancreatic tumors show high levels of hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 48 (2000), 919–922.
85. Kroemer, G., Senovilla, L., Galluzzi, L., Andre, F., Zitvogel, L., Natural and therapy-induced immunosurveillance in breast cancer. Nat. Med. 21 (2015), 1128–1138.
86. Kumar, V., Patel, S., Tcyganov, E., Gabrilovich, D.I., The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 37 (2016), 208–220.
87. Lawrence, M.S., Stojanov, P., Polak, P., Kryukov, G.V., Cibulskis, K., Sivachenko, A., Carter, S.L., Stewart, C., Mermel, C.H., Roberts, S.A., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499 (2013), 214–218.
88. Lee, K.E., Spata, M., Bayne, L.J., Buza, E.L., Durham, A.C., Allman, D., Vonderheide, R.H., Simon, M.C., Hif1a deletion reveals pro-neoplastic function of B cells in pancreatic neoplasia. Cancer Discov. 6 (2016), 256–269.
89. Leen, A.M., Sukumaran, S., Watanabe, N., Mohammed, S., Keirnan, J., Yanagisawa, R., Anurathapan, U., Rendon, D., Heslop, H.E., Rooney, C.M., et al. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol. Ther. 22 (2014), 1211–1220.
90. Legat, A., Speiser, D.E., Pircher, H., Zehn, D., Fuertes Marraco, S.A., Inhibitory receptor expression depends more dominantly on differentiation and activation than “exhaustion” of human CD8 T cells. Front Immunol., 4, 2013, 455.
91. Lemieux, E., Cagnol, S., Beaudry, K., Carrier, J., Rivard, N., Oncogenic KRAS signalling promotes the Wnt/beta-catenin pathway through LRP6 in colorectal cancer. Oncogene 34 (2015), 4914–4927.
92. Lo, A., Wang, L.C., Scholler, J., Monslow, J., Avery, D., Newick, K., O'Brien, S., Evans, R.A., Bajor, D.J., Clendenin, C., et al. Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells. Cancer Res. 75 (2015), 2800–2810.
93. Louis, C.U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G.D., Rossig, C., Russell, H.V., Diouf, O., Liu, E., et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118 (2011), 6050–6056.
94. Lu, Y.C., Robbins, P.F., Targeting neoantigens for cancer immunotherapy. Int. Immunol. 28 (2016), 365–370.
95. Lu, K., Yang, J., Li, D.C., He, S.B., Zhu, D.M., Zhang, L.F., Zhang, X.U., Chen, X.C., Zhang, B., Zhou, J., Expression and clinical significance of glucose transporter-1 in pancreatic cancer. Oncol. Lett. 12 (2016), 243–249.
96. MacIver, N.J., Michalek, R.D., Rathmell, J.C., Metabolic regulation of T lymphocytes. Annu. Rev. Immunol. 31 (2013), 259–283.
97. Makohon-Moore, A., Iacobuzio-Donahue, C.A., Pancreatic cancer biology and genetics from an evolutionary perspective. Nat. Rev. Cancer 16 (2016), 553–565.
98. Marigo, I., Zilio, S., Desantis, G., Mlecnik, B., Agnellini, A.H., Ugel, S., Sasso, M.S., Qualls, J.E., Kratochvill, F., Zanovello, P., et al. T cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells. Cancer Cell, 30, 2016, 651.
99. Mellor, A.L., Chandler, P., Baban, B., Hansen, A.M., Marshall, B., Pihkala, J., Waldmann, H., Cobbold, S., Adams, E., Munn, D.H., Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int. Immunol. 16 (2004), 1391–1401.
100. Meyer, K.A., Neeley, C.K., Baker, N.A., Washabaugh, A.R., Flesher, C.G., Nelson, B.S., Frankel, T.L., Lumeng, C.N., Lyssiotis, C.A., Wynn, M.L., et al. Adipocytes promote pancreatic cancer cell proliferation via glutamine transfer. Biochem. Biophys. Rep. 7 (2016), 144–149.
101. Michalek, R.D., Gerriets, V.A., Jacobs, S.R., Macintyre, A.N., MacIver, N.J., Mason, E.F., Sullivan, S.A., Nichols, A.G., Rathmell, J.C., Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J. Immunol. 186 (2011), 3299–3303.
102. Mocellin, S., Bronte, V., Nitti, D., Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med. Res. Rev. 27 (2007), 317–352.
103. Mohammed, S., Sukumaran, S., Bajgain, P., Watanabe, N., Heslop, H.E., Rooney, C.M., Brenner, M.K., Fisher, W.E., Leen, A.M., Vera, J.F., Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol. Ther. 25 (2017), 249–258.
104. Molon, B., Ugel, S., Del Pozzo, F., Soldani, C., Zilio, S., Avella, D., De Palma, A., Mauri, P., Monegal, A., Rescigno, M., et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 208 (2011), 1949–1962.
105. Morgan, R.A., Chinnasamy, N., Abate-Daga, D., Gros, A., Robbins, P.F., Zheng, Z., Dudley, M.E., Feldman, S.A., Yang, J.C., Sherry, R.M., et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36 (2013), 133–151.
106. Motz, G.T., Santoro, S.P., Wang, L.P., Garrabrant, T., Lastra, R.R., Hagemann, I.S., Lal, P., Feldman, M.D., Benencia, F., Coukos, G., Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 20 (2014), 607–615.
107. Mulligan, A.M., Raitman, I., Feeley, L., Pinnaduwage, D., Nguyen, L.T., O'Malley, F.P., Ohashi, P.S., Andrulis, I.L., Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry. Clin. Cancer Res. 19 (2013), 336–346.
108. Munn, D.H., Bronte, V., Immune suppressive mechanisms in the tumor microenvironment. Curr. Opin. Immunol. 39 (2016), 1–6.
109. Nagy, J.A., Chang, S.H., Dvorak, A.M., Dvorak, H.F., Why are tumour blood vessels abnormal and why is it important to know?. Br. J. Cancer 100 (2009), 865–869.
110. Nakamura, T., Shima, T., Saeki, A., Hidaka, T., Nakashima, A., Takikawa, O., Saito, S., Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci. 98 (2007), 874–881.
111. Nieman, K.M., Kenny, H.A., Penicka, C.V., Ladanyi, A., Buell-Gutbrod, R., Zillhardt, M.R., Romero, I.L., Carey, M.S., Mills, G.B., Hotamisligil, G.S., et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17 (2011), 1498–1503.
112. Nishi, K., Suzuki, K., Sawamoto, J., Tokizawa, Y., Iwase, Y., Yumita, N., Ikeda, T., Inhibition of fatty acid synthesis induces apoptosis of human pancreatic cancer cells. Anticancer Res. 36 (2016), 4655–4660.
113. O'Flanagan, C.H., Bowers, L.W., Hursting, S.D., A weighty problem: metabolic perturbations and the obesity-cancer link. Horm. Mol. Biol. Clin. Investig. 23 (2015), 47–57.
114. Olive, K.P., Jacobetz, M.A., Davidson, C.J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M.A., Caldwell, M.E., Allard, D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324 (2009), 1457–1461.
115. Ota, Y., Ishihara, S., Otani, K., Yasuda, K., Nishikawa, T., Tanaka, T., Tanaka, J., Kiyomatsu, T., Kawai, K., Hata, K., et al. Effect of nutrient starvation on proliferation and cytokine secretion of peripheral blood lymphocytes. Mol. Clin. Oncol. 4 (2016), 607–610.
116. Ottensmeier, C.H., Perry, K.L., Harden, E.L., Stasakova, J., Jenei, V., Fleming, J., Wood, O., Woo, J., Woelk, C.H., Thomas, G.J., Thirdborough, S.M., Upregulated glucose metabolism correlates inversely with CD8+ T-cell infiltration and survival in squamous cell carcinoma. Cancer Res. 76 (2016), 4136–4148.
117. Parks, S.K., Chiche, J., Pouyssegur, J., Disrupting proton dynamics and energy metabolism for cancer therapy. Nat. Rev. Cancer 13 (2013), 611–623.
118. Pauken, K.E., Sammons, M.A., Odorizzi, P.M., Manne, S., Godec, J., Khan, O., Drake, A.M., Chen, Z., Sen, D., Kurachi, M., et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354 (2016), 1160–1165.
119. Pearce, E.L., Walsh, M.C., Cejas, P.J., Harms, G.M., Shen, H., Wang, L.S., Jones, R.G., Choi, Y., Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460 (2009), 103–107.
120. Pelak, M.J., Snietura, M., Lange, D., Nikiel, B., Pecka, K.M., The prognostic significance of indoleamine-2,3-dioxygenase and the receptors for transforming growth factor beta and interferon gamma in metastatic lymph nodes in malignant melanoma. Pol. J. Pathol. 66 (2015), 376–382.
121. Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527 (2015), 249–253.
122. Peppicelli, S., Toti, A., Giannoni, E., Bianchini, F., Margheri, F., Del Rosso, M., Calorini, L., Metformin is also effective on lactic acidosis-exposed melanoma cells switched to oxidative phosphorylation. Cell Cycle 15 (2016), 1908–1918.
123. Pernick, N.L., Sarkar, F.H., Tabaczka, P., Kotcher, G., Frank, J., Adsay, N.V., Fas and Fas ligand expression in pancreatic adenocarcinoma. Pancreas 25 (2002), e36–41.
124. Pilon-Thomas, S., Kodumudi, K.N., El-Kenawi, A.E., Russell, S., Weber, A.M., Luddy, K., Damaghi, M., Wojtkowiak, J.W., Mule, J.J., Ibrahim-Hashim, A., Gillies, R.J., Neutralization of tumor acidity improves antitumor responses to immunotherapy. Cancer Res. 76 (2016), 1381–1390.
125. Pitt, J.M., Vetizou, M., Daillere, R., Roberti, M.P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I.G., Chamaillard, M., Kroemer, G., Zitvogel, L., Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity 44 (2016), 1255–1269.
126. Platten, M., von Knebel Doeberitz, N., Oezen, I., Wick, W., Ochs, K., Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors. Front Immunol., 5, 2014, 673.
127. Prosser, M.E., Brown, C.E., Shami, A.F., Forman, S.J., Jensen, M.C., Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Mol. Immunol. 51 (2012), 263–272.
128. Provenzano, P.P., Cuevas, C., Chang, A.E., Goel, V.K., Von Hoff, D.D., Hingorani, S.R., Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21 (2012), 418–429.
129. Pylayeva-Gupta, Y., Lee, K.E., Hajdu, C.H., Miller, G., Bar-Sagi, D., Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21 (2012), 836–847.
130. Pylayeva-Gupta, Y., Das, S., Handler, J.S., Hajdu, C.H., Coffre, M., Koralov, S.B., Bar-Sagi, D., IL35-producing B cells promote the development of pancreatic neoplasia. Cancer Discov. 6 (2016), 247–255.
131. Renner, K., Geiselhoringer, A.L., Fante, M., Bruss, C., Farber, S., Schonhammer, G., Peter, K., Singer, K., Andreesen, R., Hoffmann, P., et al. Metabolic plasticity of human T cells: preserved cytokine production under glucose deprivation or mitochondrial restriction, but 2-deoxy-glucose affects effector functions. Eur. J. Immunol. 45 (2015), 2504–2516.
132. Ribas, A., Hamid, O., Daud, A., Hodi, F.S., Wolchok, J.D., Kefford, R., Joshua, A.M., Patnaik, A., Hwu, W.J., Weber, J.S., et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315 (2016), 1600–1609.
133. Ridgway, R.A., Serrels, B., Mason, S., Kinnaird, A., Muir, M., Patel, H., Muller, W.J., Sansom, O.J., Brunton, V.G., Focal adhesion kinase is required for beta-catenin-induced mobilization of epidermal stem cells. Carcinogenesis 33 (2012), 2369–2376.
134. Ring, K.L., Pakish, J., Jazaeri, A.A., Immune checkpoint inhibitors in the treatment of gynecologic malignancies. Cancer J. 22 (2016), 101–107.
135. Rivlin, N., Brosh, R., Oren, M., Rotter, V., Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer 2 (2011), 466–474.
136. Rongvaux, A., Willinger, T., Martinek, J., Strowig, T., Gearty, S.V., Teichmann, L.L., Saito, Y., Marches, F., Halene, S., Palucka, A.K., et al. Development and function of human innate immune cells in a humanized mouse model. Nat. Biotechnol. 32 (2014), 364–372.
137. Rosenberg, S.A., Restifo, N.P., Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348 (2015), 62–68.
138. Rosolen, D., Kretzer, I.F., Winter, E., Noldin, V.F., Rodrigues do Carmo, I.A., Filippin-Monteiro, F.B., Cechinel-Filho, V., Creczynski-Pasa, T.B., N-Phenylmaleimides affect adipogenesis and present antitumor activity through reduction of FASN expression. Chem. Biol. Interact. 258 (2016), 10–20.
139. Royal, R.E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U.S., Sherry, R.M., Topalian, S.L., Yang, J.C., Lowy, I., Rosenberg, S.A., Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 33 (2010), 828–833.
140. Roybal, K.T., Williams, J.Z., Morsut, L., Rupp, L.J., Kolinko, I., Choe, J.H., Walker, W.J., McNally, K.A., Lim, W.A., Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell 167 (2016), 419–432.e416.
141. Rozenblum, E., Schutte, M., Goggins, M., Hahn, S.A., Panzer, S., Zahurak, M., Goodman, S.N., Sohn, T.A., Hruban, R.H., Yeo, C.J., Kern, S.E., Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 57 (1997), 1731–1734.
142. Salmon, H., Donnadieu, E., Within tumors, interactions between T cells and tumor cells are impeded by the extracellular matrix. Oncoimmunology 1 (2012), 992–994.
143. Santoiemma, P.P., Powell, D.J. Jr., Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol. Ther. 16 (2015), 807–820.
144. Scharping, N.E., Menk, A.V., Moreci, R.S., Whetstone, R.D., Dadey, R.E., Watkins, S.C., Ferris, R.L., Delgoffe, G.M., The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity 45 (2016), 374–388.
145. Schenkel, J.M., Masopust, D., Identification of a resident T-cell memory core transcriptional signature. Immunol. Cell Biol. 92 (2014), 8–9.
146. Schietinger, A., Philip, M., Krisnawan, V.E., Chiu, E.Y., Delrow, J.J., Basom, R.S., Lauer, P., Brockstedt, D.G., Knoblaugh, S.E., Hammerling, G.J., et al. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity 45 (2016), 389–401.
147. Schreiber, R.D., Old, L.J., Smyth, M.J., Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331 (2011), 1565–1570.
148. Schwarz, R.F., Ng, C.K., Cooke, S.L., Newman, S., Temple, J., Piskorz, A.M., Gale, D., Sayal, K., Murtaza, M., Baldwin, P.J., et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med., 12, 2015, e1001789.
149. Schwartz, M., Zhang, Y., Rosenblatt, J.D., B cell regulation of the anti-tumor response and role in carcinogenesis. J. Immunother. Cancer, 4, 2016, 40.
150. Seifert, L., Werba, G., Tiwari, S., Giao Ly, N.N., Alothman, S., Alqunaibit, D., Avanzi, A., Barilla, R., Daley, D., Greco, S.H., et al. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. Nature 532 (2016), 245–249.
151. Sen, D.R., Kaminski, J., Barnitz, R.A., Kurachi, M., Gerdemann, U., Yates, K.B., Tsao, H.W., Godec, J., LaFleur, M.W., Brown, F.D., et al. The epigenetic landscape of T cell exhaustion. Science 354 (2016), 1165–1169.
152. Serrels, A., Lund, T., Serrels, B., Byron, A., McPherson, R.C., von Kriegsheim, A., Gomez-Cuadrado, L., Canel, M., Muir, M., Ring, J.E., et al. Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity. Cell 163 (2015), 160–173.
153. Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348 (2015), 56–61.
154. Shi, Q., Abbruzzese, J.L., Huang, S., Fidler, I.J., Xiong, Q., Xie, K., Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin. Cancer Res. 5 (1999), 3711–3721.
155. Shi, Q., Le, X., Wang, B., Xiong, Q., Abbruzzese, J.L., Xie, K., Regulation of interleukin-8 expression by cellular pH in human pancreatic adenocarcinoma cells. J. Interferon Cytokine Res. 20 (2000), 1023–1028.
156. Singer, K., Kastenberger, M., Gottfried, E., Hammerschmied, C.G., Buttner, M., Aigner, M., Seliger, B., Walter, B., Schlosser, H., Hartmann, A., et al. Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumor. Int. J. Cancer 128 (2011), 2085–2095.
157. Singer, M., Wang, C., Cong, L., Marjanovic, N.D., Kowalczyk, M.S., Zhang, H., Nyman, J., Sakuishi, K., Kurtulus, S., Gennert, D., et al. A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T cells. Cell 166 (2016), 1500–1511.e1509.
158. Slaney, C.Y., Kershaw, M.H., Darcy, P.K., Trafficking of T cells into tumors. Cancer Res. 74 (2014), 7168–7174.
159. Smith, C., Chang, M.Y., Parker, K.H., Beury, D.W., DuHadaway, J.B., Flick, H.E., Boulden, J., Sutanto-Ward, E., Soler, A.P., Laury-Kleintop, L.D., et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov. 2 (2012), 722–735.
160. Son, J., Lyssiotis, C.A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R.M., Ferrone, C.R., Mullarky, E., Shyh-Chang, N., et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496 (2013), 101–105.
161. Speeckaert, R., Vermaelen, K., van Geel, N., Autier, P., Lambert, J., Haspeslagh, M., van Gele, M., Thielemans, K., Neyns, B., Roche, N., et al. Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. Eur. J. Cancer 48 (2012), 2004–2011.
162. Spranger, S., Bao, R., Gajewski, T.F., Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523 (2015), 231–235.
163. Steele, C.W., Karim, S.A., Leach, J.D., Bailey, P., Upstill-Goddard, R., Rishi, L., Foth, M., Bryson, S., McDaid, K., Wilson, Z., et al. CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell 29 (2016), 832–845.
164. Stromnes, I.M., Brockenbrough, J.S., Izeradjene, K., Carlson, M.A., Cuevas, C., Simmons, R.M., Greenberg, P.D., Hingorani, S.R., Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut 63 (2014), 1769–1781.
165. Stromnes, I.M., DelGiorno, K.E., Greenberg, P.D., Hingorani, S.R., Stromal reengineering to treat pancreas cancer. Carcinogenesis 35 (2014), 1451–1460.
166. Stromnes, I.M., Greenberg, P.D., Hingorani, S.R., Molecular pathways: myeloid complicity in cancer. Clin. Cancer Res. 20 (2014), 5157–5170.
167. Stromnes, I.M., Schmitt, T.M., Hulbert, A., Brockenbrough, J.S., Nguyen, H.N., Cuevas, C., Dotson, A.M., Tan, X., Hotes, J.L., Greenberg, P.D., Hingorani, S.R., T cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma. Cancer Cell 28 (2015), 638–652.
168. Stronen, E., Toebes, M., Kelderman, S., van Buuren, M.M., Yang, W., van Rooij, N., Donia, M., Boschen, M.L., Lund-Johansen, F., Olweus, J., Schumacher, T.N., Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 352 (2016), 1337–1341.
169. Su, J., Gao, T., Jiang, M., Wu, L., Zeng, W., Zhao, S., Peng, C., Chen, X., CD147 silencing inhibits tumor growth by suppressing glucose transport in melanoma. Oncotarget 7 (2016), 64778–64784.
170. Talasila, K.M., Rosland, G.V., Hagland, H.R., Eskilsson, E., Flones, I.H., Fritah, S., Azuaje, F., Atai, N., Harter, P.N., Mittelbronn, M., et al. The angiogenic switch leads to a metabolic shift in human glioblastoma. Neuro Oncol., 2016, 10.1093/neuonc/now175.
171. Tanaka, T., Sho, M., Takayama, T., Wakatsuki, K., Matsumoto, S., Migita, K., Ito, M., Hamada, K., Nakajima, Y., Endothelin B receptor expression correlates with tumour angiogenesis and prognosis in oesophageal squamous cell carcinoma. Br. J. Cancer 110 (2014), 1027–1033.
172. Tanizaki, Y., Kobayashi, A., Toujima, S., Shiro, M., Mizoguchi, M., Mabuchi, Y., Yagi, S., Minami, S., Takikawa, O., Ino, K., Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment. Cancer Sci. 105 (2014), 966–973.
173. The Cancer Genome Atlas Research Network, Integrated genomic analyses of ovarian carcinoma. Nature 474 (2011), 609–615.
174. Tham, M., Tan, K.W., Keeble, J., Wang, X., Hubert, S., Barron, L., Tan, N.S., Kato, M., Prevost-Blondel, A., Angeli, V., Abastado, J.P., Melanoma-initiating cells exploit M2 macrophage TGFbeta and arginase pathway for survival and proliferation. Oncotarget 5 (2014), 12027–12042.
175. Turtle, C.J., Hanafi, L.A., Berger, C., Gooley, T.A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T.M., et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126 (2016), 2123–2138.
176. Ueda, S.M., Yap, K.L., Davidson, B., Tian, Y., Murthy, V., Wang, T.L., Visvanathan, K., Kuhajda, F.P., Bristow, R.E., Zhang, H., Shih Ie, M., Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas. J. Oncol., 2010, 2010, 285191.
177. von Bernstorff, W., Voss, M., Freichel, S., Schmid, A., Vogel, I., Johnk, C., Henne-Bruns, D., Kremer, B., Kalthoff, H., Systemic and local immunosuppression in pancreatic cancer patients. Clin. Cancer Res. 7 (2001), 925s–932s.
178. Wainwright, D.A., Balyasnikova, I.V., Chang, A.L., Ahmed, A.U., Moon, K.S., Auffinger, B., Tobias, A.L., Han, Y., Lesniak, M.S., IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin. Cancer Res. 18 (2012), 6110–6121.
179. Walton, J., Blagih, J., Ennis, D., Leung, E., Dowson, S., Farquharson, M., Tookman, L.A., Orange, C., Athineos, D., Mason, S., et al. CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high-grade serous carcinoma. Cancer Res. 76 (2016), 6118–6129.
180. Wang, D., Saga, Y., Mizukami, H., Sato, N., Nonaka, H., Fujiwara, H., Takei, Y., Machida, S., Takikawa, O., Ozawa, K., Suzuki, M., Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy. Int. J. Oncol. 40 (2012), 929–934.
181. Wang, Q., Beaumont, K.A., Otte, N.J., Font, J., Bailey, C.G., van Geldermalsen, M., Sharp, D.M., Tiffen, J.C., Ryan, R.M., Jormakka, M., et al. Targeting glutamine transport to suppress melanoma cell growth. Int. J. Cancer 135 (2014), 1060–1071.
182. Wang, Q.J., Yu, Z., Griffith, K., Hanada, K., Restifo, N.P., Yang, J.C., Identification of T-cell receptors targeting KRAS-mutated human tumors. Cancer Immunol. Res. 4 (2016), 204–214.
183. Warburg, O., Wind, F., Negelein, E., The metabolism of tumors in the body. J. Gen. Physiol. 8 (1927), 519–530.
184. Ward, P.S., Thompson, C.B., Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21 (2012), 297–308.
185. Wesch, D., Peters, C., Siegers, G.M., Human gamma delta T regulatory cells in cancer: fact or fiction?. Front Immunol., 5, 2014, 598.
186. Wherry, E.J., Kurachi, M., Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15 (2015), 486–499.
187. Wherry, E.J., Blattman, J.N., Murali-Krishna, K., van der Most, R., Ahmed, R., Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77 (2003), 4911–4927.
188. Wherry, E.J., Ha, S.J., Kaech, S.M., Haining, W.N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J.N., Barber, D.L., Ahmed, R., Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27 (2007), 670–684.
189. Whiteside, T.L., The tumor microenvironment and its role in promoting tumor growth. Oncogene 27 (2008), 5904–5912.
190. Wilkie, S., Burbridge, S.E., Chiapero-Stanke, L., Pereira, A.C., Cleary, S., van der Stegen, S.J., Spicer, J.F., Davies, D.M., Maher, J., Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J. Biol. Chem. 285 (2010), 25538–25544.
191. Witkiewicz, A., Williams, T.K., Cozzitorto, J., Durkan, B., Showalter, S.L., Yeo, C.J., Brody, J.R., Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J. Am. Coll. Surg. 206 (2008), 849–854 discussion 854–6.
192. Witkiewicz, A.K., Nguyen, K.H., Dasgupta, A., Kennedy, E.P., Yeo, C.J., Lisanti, M.P., Brody, J.R., Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: implications for tumor progression and clinical outcome. Cell Cycle 7 (2008), 3021–3025.
193. Witkiewicz, A.K., Costantino, C.L., Metz, R., Muller, A.J., Prendergast, G.C., Yeo, C.J., Brody, J.R., Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J. Am. Coll. Surg. 208 (2009), 781–787 discussion 787–9.
194. Wofford, J.A., Wieman, H.L., Jacobs, S.R., Zhao, Y., Rathmell, J.C., IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival. Blood 111 (2008), 2101–2111.
195. Xu, L., Fidler, I.J., Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells. Cancer Res. 60 (2000), 4610–4616.
196. Xu, Y., Chaudhury, A., Zhang, M., Savoldo, B., Metelitsa, L.S., Rodgers, J., Yustein, J.T., Neilson, J.R., Dotti, G., Glycolysis determines dichotomous regulation of T cell subsets in hypoxia. J. Clin. Invest. 126 (2016), 2678–2688.
197. Yang, L., Achreja, A., Yeung, T.L., Mangala, L.S., Jiang, D., Han, C., Baddour, J., Marini, J.C., Ni, J., Nakahara, R., et al. Targeting stromal glutamine synthetase in tumors disrupts tumor microenvironment-regulated cancer cell growth. Cell Metab. 24 (2016), 685–700.
198. Ying, H., Kimmelman, A.C., Lyssiotis, C.A., Hua, S., Chu, G.C., Fletcher-Sananikone, E., Locasale, J.W., Son, J., Zhang, H., Coloff, J.L., et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149 (2012), 656–670.
199. Zeng, G., Germinaro, M., Micsenyi, A., Monga, N.K., Bell, A., Sood, A., Malhotra, V., Sood, N., Midda, V., Monga, D.K., et al. Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. Neoplasia 8 (2006), 279–289.
200. Zhang, X., Hao, J., Development of anticancer agents targeting the Wnt/beta-catenin signaling. Am. J. Cancer Res. 5 (2015), 2344–2360.
201. Zitvogel, L., Ayyoub, M., Routy, B., Kroemer, G., Microbiome and anticancer immunosurveillance. Cell 165 (2016), 276–287.
202. Zschaler, J., Schlorke, D., Arnhold, J., Differences in innate immune response between man and mouse. Crit. Rev. Immunol. 34 (2014), 433–454.